Pulse Biosciences, Inc (PLSE) financial statements (2021 and earlier)

Company profile

Business Address 3957 POINT EDEN WAY
HAYWARD, CA 94545
State of Incorp. DE
Fiscal Year End December 31
SIC 3841 - Surgical and Medical Instruments and Apparatus (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments127513816
Cash and cash equivalents1275132
Short-term investments   3514
Other undisclosed current assets1020900
Total current assets:2226603817
Noncurrent Assets
Operating lease, right-of-use asset95
Property, plant and equipment23230
Intangible assets, net (including goodwill)77899
Goodwill33333
Intangible assets, net (excluding goodwill)45567
Other noncurrent assets0000 
Total noncurrent assets:1916101110
TOTAL ASSETS:4142715026
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities74321
Accounts payable22110
Accrued liabilities52111
Deferred rent credit  0
Deferred revenue and credits0 
Other undisclosed current liabilities1    
Total current liabilities:84321
Noncurrent Liabilities
Long-term debt and lease obligation117   
Operating lease, liability117
Liabilities, other than long-term debt  12 
Deferred revenue and credits2 
Deferred rent credit  1
Other undisclosed noncurrent liabilities(11)    
Total noncurrent liabilities:11712 
Total liabilities:1811441
Stockholders' equity
Stockholders' equity attributable to parent2331664625
Common stock00000
Additional paid in capital1951531428438
Accumulated other comprehensive income (loss)(0)0(0)(0)(0)
Accumulated deficit(173)(123)(76)(38)(13)
Total stockholders' equity:2331664625
TOTAL LIABILITIES AND EQUITY:4142715026

Income statement (P&L) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
Revenues
(Net Investment Income)
01000
Cost of revenue
(Cost of Goods and Services Sold)
(1)(1)(1)(1)(1)
Gross profit:(0)0(0)(1)(0)
Operating expenses(50)(48)(38)(26)(10)
Other undisclosed operating income11111
Operating loss:(50)(47)(38)(26)(10)
Nonoperating expense
(Investment Income, Nonoperating)
(0)    
Other undisclosed income from continuing operations before equity method investments, income taxes0    
Loss from continuing operations before income taxes:(50)(47)(38)(26)(10)
Income tax expense(0)    
Net loss:(50)(47)(38)(26)(10)
Other undisclosed net income attributable to parent0    
Net loss available to common stockholders, diluted:(50)(47)(38)(26)(10)

Comprehensive Income ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
Net loss:(50)(47)(38)(26)(10)
Comprehensive loss:(50)(47)(38)(26)(10)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(0)00(0)(0)
Comprehensive loss, net of tax, attributable to parent:(50)(47)(37)(26)(10)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: